Heritage Wealth Management LLC grew its position in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 97.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,291 shares of the company’s stock after acquiring an additional 638 shares during the quarter. Heritage Wealth Management LLC’s holdings in Pacira BioSciences were worth $72,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently modified their holdings of PCRX. IFP Advisors Inc increased its holdings in shares of Pacira BioSciences by 2,680.0% in the 3rd quarter. IFP Advisors Inc now owns 695 shares of the company’s stock valued at $39,000 after acquiring an additional 670 shares during the last quarter. Amundi Pioneer Asset Management Inc. bought a new stake in shares of Pacira BioSciences in the 1st quarter valued at approximately $65,000. Liberty Wealth Management LLC increased its holdings in shares of Pacira BioSciences by 5,968.2% in the 2nd quarter. Liberty Wealth Management LLC now owns 4,005 shares of the company’s stock valued at $66,000 after acquiring an additional 3,939 shares during the last quarter. Maverick Capital Ltd. bought a new stake in shares of Pacira BioSciences in the 2nd quarter valued at approximately $67,000. Finally, HM Payson & Co. increased its holdings in shares of Pacira BioSciences by 2,400.0% in the 2nd quarter. HM Payson & Co. now owns 1,250 shares of the company’s stock valued at $76,000 after acquiring an additional 1,200 shares during the last quarter.
NASDAQ:PCRX opened at $64.08 on Friday. Pacira BioSciences, Inc. has a 1 year low of $45.05 and a 1 year high of $80.00. The stock has a market cap of $2.85 billion, a price-to-earnings ratio of 47.12 and a beta of 1.00. The business has a fifty day moving average of $57.85 and a 200-day moving average of $56.90. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.34 and a current ratio of 3.64.
A number of research analysts recently commented on the company. Northland Securities upped their price objective on Pacira BioSciences from $57.00 to $61.00 in a research note on Tuesday, January 4th. Barclays upped their price objective on Pacira BioSciences from $91.00 to $92.00 and gave the stock an “overweight” rating in a research note on Friday, November 5th. HC Wainwright upped their price objective on Pacira BioSciences from $80.00 to $86.00 and gave the stock a “buy” rating in a research note on Thursday, November 4th. Needham & Company LLC upped their price objective on Pacira BioSciences from $80.00 to $84.00 and gave the stock a “buy” rating in a research note on Monday, October 18th. Finally, Wedbush restated a “buy” rating and set a $97.00 price objective on shares of Pacira BioSciences in a research note on Friday, January 7th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $81.09.
Pacira BioSciences Profile
Pacira Biosciences, Inc is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam.The company was founded in December 2006 and is headquartered in Parsippany, NJ.
Featured Story: The role of implied volatility with call option volume
Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira BioSciences, Inc. (NASDAQ:PCRX).
Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.